University of Colorado Anschutz Cancer Center member Bradley Corr, MD, professor of gynecologic oncology in the CU Anschutz School of Medicine, has been named deputy associate medical director of the center’s Cancer Clinical Trials Office (CCTO).
In the new role, Corr will work with CCTO medical director Jennifer Diamond, MD, and associate director for clinical research Christopher Lieu, MD, to ensure the overall success of the CCTO. That includes working collaboratively with clinical operations and administrative leadership to ensure successful operations, managing resources to accommodate growth in research activities, and overseeing adherence to regulatory requirements. Corr also will help oversee matters pertaining to the safe and ethical conduct of clinical trials conducted by the CCTO.
“Dr. Lieu and Dr. Diamond have already identified some areas of high need for the CCTO, including increasing trial enrollment, increasing trial availability, and opening timelines for clinical trials to ensure that we can provide all of our patients with the best opportunities,” Corr says. “I'm passionate about the cancer center, I'm passionate about clinical trials, and this is a great opportunity for me to use my experience to help the CCTO.”
Corr has been involved with multiple clinical trials over the past decade, including a current trial that is offering new hope to ovarian cancer patients who don’t respond to existing therapy.
“I've been involved in clinical trials at all phases, phase I through phase IV, and I've seen treatment get approved through the FDA and become available to our patients off of trial,” he says. “The University of Colorado is a leader in being able to offer therapies earlier and with great success. Over time, I've had the good fortune to be able to see patients benefit from clinical trials and live longer.
Conducting clinical trials is vital to the research efforts of the CU Anschutz Cancer Center, Corr says — a fact underscored by the center’s National Comprehensive Cancer Network (NCCN) designation.
“Clinical trials are important on so many levels,” he says. “First and foremost, they allow us to provide our patients with the best opportunities, the latest science, and often improved outcomes. And as an NCCN-accredited center, accruals and clinical trial opportunities are important for that accreditation. Clinical trials help advance the research on different malignancies within all our disease sites.”
Corr says he hopes to build upon his existing relationships with oncologists inside and outside of the cancer center to offer assistance on specific trials and to make a broader impact on the administrative and policy side.
“Dr. Corr has consistently demonstrated exceptional leadership and vision within the cancer clinical research community,” Lieu says. “His extensive experience designing and executing complex, multicenter trials, combined with his deep understanding of trial operations, makes him the perfect fit for this role. Dr. Corr is incredibly collaborative and has a steadfast commitment to patient care that will add immensely to the culture and effectiveness of the CCTO.”